KMPHARMACEUTICAL Co.,Ltd. Stock

Equities

A225430

KR7225430008

Corporate Financial Services

End-of-day quote Korea S.E. 06:00:00 2024-04-22 pm EDT 5-day change 1st Jan Change
830 KRW +1.84% Intraday chart for KMPHARMACEUTICAL Co.,Ltd. -0.24% -15.13%
Dynamic Chart
Km Pharmaceutical Co., Ltd. completed the acquisition of IBKS No.3 Special Purpose Acquisition Company in a reverse merger transaction. CI
IBKS No.3 Special Purpose Acquisition Company‘s Equity Buyback announced on March 1, 2018, has expired. CI
Sungkeun Mun acquired 4.9% stake in Km Pharmaceutical Co., Ltd. from K Investment Co., Ltd., Shinhan Investment Corp., KTB Growth Industry Hedge Fund, KTB Mezzanine Private Investment Trust No. 73, and KTB Mezzanine Private Investment Trust No. 74, funds managed by KTB Asset Management Co., Ltd for KRW 2.7 billion. CI
Km Pharmaceutical Co., Ltd. cancelled the acquisition of 4% in Iconix Co., Ltd. from Wonjung Kim, Hyunsoo Seo, Changhwan Shin, Youngsik Im and Miyoung Jung. CI
Km Pharmaceutical Co., Ltd. announces an Equity Buyback. CI
Km Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Km Pharmaceutical Co., Ltd. entered into an agreement to acquire IBKS No.3 Special Purpose Acquisition Company in a reverse merger transaction. CI
K Investment Co., Ltd. acquired 1% stake in Km Pharmaceutical Co., Ltd. from Mun, Sung Keun for approximately KRW 500 million. CI
Juyong Shin acquired 0.18% stake in Km Pharmaceutical Co., Ltd. from Sung Keun Mun for KRW 90.4 million. CI
Shinhan Investment Corp., KTB Growth Industry Hedge Fund, KTB Mezzanine Private Investment Trust No. 73 and KTB Mezzanine Private Investment Trust No. 74 funds managed by KTB Asset Management Co., Ltd acquired 3.92% in Km Pharmaceutical Co., Ltd. from Mun, Sung Keun for KRW 2 billion. CI
Km Pharmaceutical Co., Ltd. signed a contract to acquire 4% in Iconix Co., Ltd. from Wonjung Kim, Hyunsoo Seo, Changhwan Shin, Youngsik Im and Miyoung Jung for KRW 4 billion. CI
ST Capital Co., Ltd and Youngin Seo acquired 0.15% stake in Km Pharmaceutical Co., Ltd from Sunggeun Moon for KRW 75 million. CI
ST Capital Co., Ltd acquired an additional 0.25% stake in Km Pharmaceutical Co., Ltd from Sunggeun Mun for approximately KRW 130 million. CI
ST Capital Co., Ltd and Youngin Seo acquired 0.74% stake in Km Pharmaceutical Co., Ltd from Sunggeun Moon for approximately KRW 380 million. CI
Sunggeun Moon sold 0.79% stake in Km Pharmaceutical Co., Ltd. for KRW 400 million. CI
More news
1 day+1.84%
1 week-0.24%
Current month-12.91%
1 month-8.99%
3 months-18.87%
6 months-20.19%
Current year-15.13%
More quotes
1 week
801.00
Extreme 801
833.00
1 month
801.00
Extreme 801
976.00
Current year
801.00
Extreme 801
1 148.00
1 year
801.00
Extreme 801
1 450.00
3 years
801.00
Extreme 801
3 200.00
5 years
801.00
Extreme 801
5 880.00
10 years
801.00
Extreme 801
6 650.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 18-09-10
Director/Board Member 40 -
Comptroller/Controller/Auditor 50 15-12-31
Members of the board TitleAgeSince
Chief Executive Officer 56 18-09-10
Corporate Officer/Principal 62 11-12-31
Director/Board Member 48 12-12-31
More insiders
KMPHARMACEUTICAL Co.,Ltd., formerly IBKS No.3 Special Purpose Acquisition Company, is a Korea-based company mainly engaged in the manufacturing and distribution of oral hygiene products and cosmetics. Oral hygiene products include toothpaste, toothbrush and goggles. Cosmetic products consist of shampoo, body wash, sun cream, moisturizing cream, as well as lip balm and others. The company distributes its products within domestic market and to overseas markets including North America, South America, Europe, China, Malaysia, Singapore, Vietnam and Australia.
More about the company
  1. Stock Market
  2. Equities
  3. A225430 Stock